Advances in Multiple Myeloma

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

Newly Diagnosed Multiple Myeloma

Advances in MM

Car/Len/Dex +/- ASCT or Car/Cyclo/Dex + ASCT in NDMM: The Forte Study

FORTE Results: MRD With Car/Len/Dex or Cyclophosphamide/Car/Dex in NDMM

ALCYONE Study: Dara/VMP vs VMP in ND Elderly Patients Ineligible for ASCT: Subgroup Analysis

Key Takeaways

Key Takeaways (cont)

Relapsed and Refractory Multiple Myeloma

Background

ARROW Study Once- vs Twice-Weekly Kd in RRMM

OPTIMISMM Study PVd vs Vd in RRMM With Prior Lenalidomide Exposure

MMY1001 Study D-Kd in Lenalidomide-Refractory, Relapsed MM

PAVO Study Subcutaneous Daratumumab in RRMM

ELOQUENT-3 Study EPd vs Pd for RRMM

Key Takeaways

Emerging Agents in Multiple Myeloma

Rationale for Emerging Agents in MM

CAR T Cell Therapy bb2121 in RRMM

Venetoclax in RRMM with t(11;14)

Venetoclax/Carfilzomib/Dex in RRMM

Isatuximab in MM

Selinexor Combinations

Selinexor + Dex in Penta-Refractory MM STORM Study

Pembrolizumab Current Status in MM

Key Takeaways

Clinical Practice Implications

Recent Data Implications for NDMM

Recent Data Implications for RRMM

Future Directions

Abbreviations

Abbreviations (cont)

Abbreviations (cont)

Abbreviations (cont)